OGEN.US Oragenics Inc

Healthcare Biotechnology USA Stocks
0.1980 USD
Close of Nov 17, 2026
0.1700 1.11
Market cap
USD 893K
P/E
-
P/B
0.25x
ROE
-895.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is OGEN.US undervalued?

Graham number

The Graham number of Oragenics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Oragenics Inc fundamental analysis

No fundamental analysis for Oragenics Inc yet.

Oragenics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Oragenics Inc

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of…

Full company profile